Scenesse drug implant tans skin without cancer risk

By Admin
Sun worshippers around the world are rejoicing after scientists have developed a method to get a three-month long tan without the risk of developing sk...

Sun worshippers around the world are rejoicing after scientists have developed a method to get a three-month long tan without the risk of developing skin cancer.

They have come up with an under-the-skin implant which triggers the production of melanin, a skin pigment that controls its colour and also helps to protects against UV radiation.

As the implant releases the melanin chemical, skin will appear darker to resemble a tan, thereby potentially removing the need for people to use sunbeds.

However, rather than being a deliberate cosmetic invention, the Scenesse drug implant was initially developed to help treat skin conditions such as erythropoietic protoporphyria (EPP).

To read the latest edition of Healthcare Global, click here

The drug is now undergoing trials to see how it can treat the pigment disorder vitiligo, which is estimated to affect 45 million people across the world.  

It is also hoped the Scenesse implant could be a potential treatment for organ transplant patients, who have a severely heightened risk of developing skin cancer.

The implant, which is about the size of a grain of rice, has been developed by manufacturer Clinuvel

The research was carried out by a team from Manchester University and a professor of experimental dermatology, Lesley Rhodes, said: “Potentially, it does offer an alternative to commercial sunscreens and there are lots of senior scientists who are convinced it is dermatology.”

However, she did point out that more research needs to be until it was made widely available on the market.

In a statement, manufacturer Clinuvel said:  “To date, Clinuvel has spent over $80 million developing the Scenesse implant drug product as a therapeutic photoprotective drug for patients who are most at risk from UV and sun exposure.

“Trials to date have raised no serious safety concerns; thus far the drug is well tolerated by patients. The implant drug product has been chosen for its ease of use in dermatology.”

The ability of the implant to prevent skin cancer has been recognised and well received by the world’s biggest cancer charity, Cancer Research.


Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare